IDEAYA Biosciences: Buy Rating Affirmed Amid FDA Breakthrough and Promising Clinical Developments

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on IDEAYA Biosciences (IDYA – Research Report) and keeping the price target at $58.00.

Charles Zhu has given his Buy rating due to a combination of factors surrounding IDEAYA Biosciences. The recent FDA Breakthrough Therapy Designation for darovasertib in neoadjuvant uveal melanoma is a significant milestone, suggesting potential acceleration in FDA interactions and review processes. This development is timely as IDEAYA is preparing to initiate a Phase 3 registrational study in the near future, which could enhance the company’s clinical and regulatory trajectory.
Furthermore, the FDA’s decision was based on updated clinical data that demonstrated substantial clinical benefits, particularly in the enucleation cohort, where more than half of the patients had their eye saved. Management’s discussions with the FDA revealed a positive outlook on the data, which is expected to be further supported by upcoming readouts in 2025. These factors, combined with IDEAYA’s narrowed guidance on future data updates and the potential for vision improvement in the plaque cohort, underpin Zhu’s optimistic outlook on the stock.